ArticleEuropean heart journal open2026
Mitral annulus calcification and the risk of infective endocarditis: insights from DANCAVAS screening trials.
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Risk stratification in infective endocarditis (IE) does not incorporate structural substrates involved in early disease initiation. The aim of this study was to examine the association between mitral annulus calcification (MAC) burden and the risk of IE. Methods and results: This substudy utilized the population-based DANCAVAS cohort undergoing non-contrast computed tomography (CT) with MAC quantification with follow-up until 19 August 2025. The primary outcome was incidence rates and 10-year risk of IE across three exploratory categorical groups: No MAC (0 arbitrary units (AU)), MAC 1-299 AU, and MAC ≥300 AU. A total of 14 793 participants were included with mean (SD) age, 66.9 (3.8) years, and 14 053 males (95.0%). Median MAC was 13 AU (IQR3.3-56.2) in the MAC 1-299 group and 680 AU (IQR447-1271) in the MAC ≥300 group. IE incidence rate per 10 000 person-years was 1.92 for no MAC, 2.48 for MAC 1-299, and 21.3 for MAC ≥300 ( Conclusion: Greater MAC burden was associated with a higher risk of IE. In exploratory categorical analyses, MAC ≥300 AU was associated with the highest observed risk, although these findings should be interpreted with caution given the limited number of events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.